|
Video: What is a Stock Split?
|
|
Ocuphire Pharma is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Co.'s primary product candidate, Nyxol® Eye Drops, is a once-daily eye drop formulation of phentolamine mesylate designed to reduce pupil diameter and improve visual acuity. Co.'s second product candidate, APX3330, is a twice-a-day oral tablet designed to target multiple pathways relevant to retinal and choroidal (the vascular layer of the eye) diseases such as diabetic retinopathy and diabetic macular edema which, if left untreated, can result in permanent visual acuity loss and eventual blindness. According to our OCUP split history records, Ocuphire Pharma has had 1 split. | |
|
Ocuphire Pharma (OCUP) has 1 split in our OCUP split history database. The split for OCUP took place on November 06, 2020. This was a 1 for 4 reverse split, meaning for each 4 shares of OCUP owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 250 share position following the split.
When a company such as Ocuphire Pharma conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the OCUP split history from start to finish, an original position size of 1000 shares would have turned into 250 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Ocuphire Pharma shares, starting with a $10,000 purchase of OCUP, presented on a split-history-adjusted basis factoring in the complete OCUP split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/30/2014 |
|
End date: |
04/26/2024 |
|
Start price/share: |
$3.80 |
|
End price/share: |
$1.61 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-57.63% |
|
Average Annual Total Return: |
-8.23% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$4,237.50 |
|
Years: |
10.00 |
|
|
|
Date |
Ratio |
11/06/2020 | 1 for 4 |
|
|